Work partly funded by ARDAT and originally developed by Professor Mimoun Azzouz and team at the University of Sheffield has been granted IND approval by the FDA. “The preclinical results with BFB-101 have demonstrated promising activity and safety, and we look forward to bringing this treatment to SPG47 patients where the unmet need is incredibly high. It has been a huge excitement for overseeing the progress of this innovation from discovery stage all the way to IND approval” added Professor Mimoun Azzouz, Founder and Chief Scientific Officer of BlackfinBio. Further details can be accessed via the link.
